Intermittent androgen suppression in patients with prostate cancer

BJU International

Volumn 91, Issue 1, 2003, Pages 18-22

  De La Taille, A ^a,b   Zerbib, M ^a   Conquy, S ^a   Amsellem Ouazana, D ^a   Thiounn, N ^a   Flam, T A ^a   Debre B ^a  

^a CHU Cochin ^*  (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Hormone therapy; Intermittent androgen suppression; Metastasis; Prostate cancer; Radical prostatectomy

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; ANDROGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; CHEMICAL ANALYSIS; CLINICAL ARTICLE; GLEASON SCORE; LYMPH NODE; MULTIVARIATE ANALYSIS; STATISTICAL ANALYSIS; TIME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0037236836     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04015.x     Document Type: Article

References (28)

1. Bruchovsky N, Rennie PS, Coldman AJ et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275-82
2. Akakura K, Bruchovsky N, Goldenberg LS et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993; 71: 2782-90
3. Gleave ME, Hsieh JT, Wuh HC, von Eschenback AC, Chung LWK. Serum PSA levels in mice bearing human prostate LNCaP tumours are determined by tumour volume and endocrine growth factors. Cancer Res 1992; 52: 1598-605
4. Sato N, Gleave ME, Goldenberg SL et al. Intermittent androgen suppression delays time to androgen independent progression in LNCaP prostate tumour model. J Urol 1995; 153: 282A
5. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998; 51: 137-44
6. Klotz LH, Herr HW, Morse MJ et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546-50
7. Goldenberg LS, Bruchovsky N, Gleave ME et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1993; 45: 839-44
8. Higano CS, Ellis W, Russell K et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996; 48: 800-4
9. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged off therapy. Oncologist 2000; 5: 45-52
10. Theyer G, Hamilton G. Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology 1998; 52: 353-9
11. Oliver RT, Williams G, Paris AM, Blandy JP. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 1997; 49: 79-82
12. Horwich A, Huddart RA, Gadd J et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998; 81: 96-9
13. Crook JM, Szumacher E, Malone S et al. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53: 520-4
14. Kurek R, Renneberg H, Lubben G, Kienle E, Tunn UW. Intermittent complete androgen suppression in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999; 35 (Suppl. 1): 27-31
15. Bales GT, Sinner MD, Kim JH, Chodak GW. Impact of intermittent androgen deprivation on quality of life. J Urol 1996; 155: 1069A
16. Zerbib M, Conquy S, Gerbaud PF et al. Efficacy and effect on quality of life (QOL) of intermittent androgen deprivation for prostate cancer treatment. Eur Urol 1998; 33 (Suppl. 1): 89 (A354)
17. Grossfeld GD, Small EJ, Lubeck DP, Latini D, Broering JM, Carroll PR. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology 2001; 58 (Suppl. 1): 56-64
18. Bouchot O, Lenormand L, Karam G et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000; 38: 543-9
19. DaSilva C, Bono A, Whelan P et al. Phase III study of intermittent MAB versus continuous MAB International Cooperative Group Study. Eur Urol 1999; 35: A54
20. Rambeaud JJ. Intermittent complete androgen suppression in metastatic prostate cancer. Eur Urol 1999; 35 (Suppl. 1): 32-6
21. Irani J, Baumert H, Bon D et al. Minimum two year treatment with LH-RH analogues: are low serum testosterone levels maintained after treatment interruption? J Urol 1997; 157: 333A
22. Hall MC, Fritzsch RJ, Sagalowsky AI et al. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999; 53: 898-903
23. Denis L, Murphy GP. Overview over phase III trials on combined androgen treatment in patients with metastatic carcinoma of the prostate. Cancer 1993; 72 (Suppl. 1): 3888-95
24. Prostate Cancer Trialists' Collaborative Group. Maximum androgen suppression in advanced prostate cancer. an overview of the randomised trials. Lancet 1999; 355: 1491-8
25. Schmitt B, Wilt TJ, Schellhammer PF et al. Combined androgen suppression with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001; 57: 727-32
26. Waltregny D, Boca P, Nicolas H et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone naïve prostate cancer: results of a randomized prospective multicenter clinical trial. J Urol 2002; 168 (Suppl): A701
27. Calais F, Bono A, Whelan P et al. Phase III study of intermittent MAB versus continuous MAB international cooperative study. Eur Urol 2002; 41 (Suppl): A531
28. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7